Table 2 Characteristics of validations of included studies
| Â | Framingham | Framingham | PCE | WHO charts for east Asia | Asian equation | China-PAR b | Risk model (Optimal) b | Risk model (Simplied) b |
|---|---|---|---|---|---|---|---|---|
|  | Wilson1998 | D’Agostino2008 | Stone2013 | WHO2019 | Asia2007 | Yang2016 | Wu2006 | Wu2006 |
|  | n = 2 | n = 5 | n = 11 | n = 2 a | n = 1 | n = 6 | n = 1 | n = 1 |
Location of the validation cohorts | ||||||||
 Single-province in mainland China | 0 | 3 | 2 | 0 | 0 | 4 | 0 | 0 |
 Multi-province in mainland China | 2 | 0 | 6 | 2 | 1 | 2 | 1 | 1 |
 China HongKong | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
 Ethic Chinese | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Participant age in the validation cohorts | ||||||||
 Min, Median | 30 | 30 | 35 | 40 | 30 | 35 | 35 | 35 |
 Max, Median | 75 | 74 | 79 | 80 | 75 | 74 | 59 | 59 |
Size of the Validation cohorts | ||||||||
 Sample size, median[range] | 27,901 [25,682–30,121] | 7157 [438–27,721] | 20,886 [425–70,838] | 23,329 [27,321–29,337] | 25,682 | 21,631 [3347–70,838] | 15,100 | 15,100 |
 Events,median[range] | 366 [191–542] | 880 [45–3732] | 622 [21–1493] | 1070 [1045–1091] | 542 | 1209 [190–3732] | 347 | 347 |
Recruitment years of the Validation cohorts | ||||||||
  < 2000 year | 2 | 2 | 6 | 2 | 1 | 1 | 1 | 1 |
 2001 ~ 2010 year | 0 | 2 | 4 | 0 | 0 | 5 | 0 | 0 |
  > 2010 year | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |